Precipio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRPO research report →
Price Chart
About the company
Precipio, Inc. , based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers.
- CEO
- Ilan Danieli
- IPO
- 2017
- Employees
- 61
- HQ
- New Haven, CT, US
Get TickerSpark's AI analysis on PRPO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.11M
- P/E
- -28.70
- Fwd P/E
- 0.63
- PEG
- 0.35
- P/S
- 1.09
- P/B
- 2.09
- EV/EBITDA
- 132.87
- Div Yield
- 0.00%
- Gross Margin
- 43.21%
- Op Margin
- -5.18%
- Net Margin
- -4.00%
- ROE
- -7.84%
- ROIC
- -7.99%
Latest fiscal year · YoY change
- Revenue
- $24.05M+50.6%
- Gross Profit
- $10.71M+41.6%
- Op Income
- $-1,202,000
- Net Income
- $-363,000+91.5%
- EPS
- $-0.23+92.2%
- OCF Growth
- +56.0%
- FCF Growth
- +66.2%
- 52W High
- $33.63
- 52W Low
- $17.30
- 50D MA
- $22.15
- 200D MA
- $24.70
- Beta
- 1.30
- RSI (14)
- 36
- Avg Volume
- 79.50K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Precipio said Q3 revenue rose to $7.3 million as product sales topped $1 million for the first time, while management laid out an aggressive 2027 growth plan focused on scaling distribution and expanding the sales team.· November 10, 2026
- Q3 total revenue increased to $7.3 million from about $7.0 million in Q2.
- Pathology revenue was about $6.3 million, and product revenue exceeded $1 million for the first time in a quarter.
- Adjusted EBITDA was about $400,000, about flat with Q2, and operating cash flow was about $600,000 versus about $700,000 in Q2.
- Quarter-end cash was above $3.5 million, up about $0.5 million during Q3 and versus about $2.3 million a year earlier.
- Management set 2027 exit run-rate targets of more than $10 million for products, about $30 million for pathology, and more than $40 million combined.
Precipio reported Q3 2026 total revenue of approximately $7.3 million, up from approximately $7.0 million in Q2. Pathology revenue was approximately $6.3 million, product revenue exceeded $1 million for the first time, adjusted EBITDA was approximately $400,000, and operating cash flow was approximately $600,000 versus approximately $700,000 in Q2. Total cash increased by approximately $0.5 million during Q3 to above $3.5 million, compared with approximately $2.3 million a year earlier. Looking ahead, management is targeting an annualized product revenue run rate above $10 million and pathology run rate of approximately $30 million by the end of 2027, for combined annualized run rate above $40 million; they emphasized these are exit-rate targets, not full-year 2027 revenue forecasts.
Ilan Danieli framed 2025 as the year Precipio became cash flow positive and financially independent, and 2026 as the year it learned how to make distribution work as a scalable sales channel. His tone was upbeat and more assertive than in prior periods, saying 2027 will be the year the company shifts from validation to accelerated growth. He emphasized new marketing, more commercial hires, tighter coordination across product and pathology, and stronger evidence-building through conferences, publications, and key opinion leaders.
Zaki Sabet focused on operating leverage and the company’s ability to scale without major new capital investment. He said Precipio’s existing infrastructure could support about $100 million in annual revenue, roughly split between pathology and product manufacturing, without significant additional capital in core facilities and equipment. He argued that this creates room to grow revenue, improve margins, and increase profitability as volume expands.
Analysts focused on how quickly new sales hires can translate into product revenue, the current size of the sales force, and whether the company’s growth targets imply pricing pressure or weak demand. Management said the sales force is currently 4 people and plans to roughly double it next year, while noting customer onboarding can take anywhere from about 3 months to 18 months and often 9 to 12 months on average. They denied any price declines or demand weakness, said the pipeline is strong enough that converting half of it would get them to the $10 million product run-rate target, and explained that the slower 2026 growth reflected an intentional strategy to learn the distributor model before scaling up.
The company is already cash flow positive, added cash in the quarter, and says it no longer needs outside capital to survive. Management believes it has now figured out the distributor playbook, product revenue has crossed $1 million per quarter, and the current pipeline plus planned sales-team expansion could support a much higher run rate by 2027.
The growth targets depend on long and uncertain customer onboarding cycles, with management citing timelines from 3 months to 18 months and average cycles of 9 to 12 months. Product revenue growth was only about $100,000 sequentially in Q3, and even management acknowledged it is not satisfied with the pace, while the 2027 goals require significant execution from a still-small sales organization.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 78.6%
- Shares Outstanding
- 1.79M
- Float Shares
- 1.41M
of shares held by institutions
17 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Two Sigma Investments, LP | 77.04K | ▲ 77.04K |
| Vanguard Capital Management LLC | 57.44K | ▲ 11.29K |
| Blackrock, Inc. | 34.41K | ▼ 245 |
| Jane Street Group, LLC | 32.47K | ▲ 32.47K |
| Vanguard Group Inc | 25.56K | ▲ 5.37K |
| Geode Capital Management, LLC | 17.18K | ▼ 1.51K |
| Xtx Topco Ltd | 15.71K | ▲ 6.26K |
| Citadel Advisors LLC | 14.71K | ▼ 402 |
| Trexquant Investment LP | 11.85K | ▲ 11.85K |
| Ubs Group AG | 9.93K | ▲ 9.59K |
| Vanguard Fiduciary Trust Co | 9.41K | 0 |
| Hrt Financial LP | 8.78K | ▲ 8.78K |
Held by 27 ETFs
Biggest fund positions in PRPO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Cohen David Seth | other | 582 |
| Oct 15, 26 | Valauri Christina Rizopoulos | other | 122 |
| Jul 15, 26 | Valauri Christina Rizopoulos | other | 108 |
| Jul 15, 26 | Cossman Jeffrey | other | 416 |
| Jul 15, 26 | Cohen David Seth | other | 520 |
| May 21, 26 | SANDBERG RICHARD A | sell | 900 |
| May 20, 26 | SANDBERG RICHARD A | sell | 2,034 |
| May 19, 26 | SANDBERG RICHARD A | sell | 600 |
| May 20, 26 | SANDBERG RICHARD A | sell | 500 |
| Apr 15, 26 | Valauri Christina Rizopoulos | other | 93 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRPO coverage
Recent articles, reports, and earnings notes.
No research on PRPO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRPO report →PRPO Stock Slips Post Q3 Earnings Despite Revenue and Product Growth
zacks.com · Nov 16
Precipio, Inc. (PRPO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Precipio Announces Q3-2026 Financial Results
globenewswire.com · Nov 10
Precipio Announces Q3-2026 Shareholder Update Call
globenewswire.com · Oct 28
Precipio (NASDAQ:PRPO) Shares Cross Below 200-Day Moving Average – Here’s Why
defenseworld.net · Oct 23
Precipio: Management Dreams Big, Institutions Have A Toe In
seekingalpha.com · Oct 12
Precipio (NASDAQ:PRPO) Share Price Crosses Below 200 Day Moving Average – What’s Next?
defenseworld.net · Oct 7
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
zacks.com · Sep 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.